In 2023, when Moderna announced a $40 million investment in cybersecurity, skeptics questioned the move. Was it an overreaction? A necessary evil? Twelve months later, the numbers told a different story.

Wall Street analysts questioned the expense. Twelve months later, the company's operational efficiency had increased by 31%, research timelines shortened by months, and partnership negotiations accelerated significantly.

• Operational efficiency increased by 31%

• Research timelines were shortened by months

• Partnership negotiations accelerated significantly

The message was loud and clear: In modern biotech, cybersecurity isn’t just about defense—it’s a profit engine.

Last year, a promising biotech startup lost everything. Not because their science was flawed, but because of a compliance oversight that could have been prevented. Their story isn't unique—but yours doesn't have to follow the same path.

Picture this: Your biotech firm just made a breakthrough discovery that could revolutionize cancer treatment.

But while your competitors are already racing to market, your teams are stuck waiting for computational resources to process crucial data.

In today's high-stakes biotech industry, scenarios like this aren't just frustrating—they're the difference between market leadership and playing catch-up.